Biocon Ltd

The approved product is indicated for the treatment of adults with type-2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control, and reduce the risk of hospitalization for heart failure in adults with type-2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors. Dapagliflozin Tablets will be manufactured at Biocon's FDA-approved facilities, in compliance with global quality and regulatory standards. This approval further strengthens Biocon's expanding diabetes portfolio, which spans oral solid dosage formulations, biosimilar insulin, and complex GLP-1 peptides, reinforcing the company's integrated approach to addressing the evolving needs of people living with diabetes globally,' the Bengaluru-based company said in a statement. Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases. The company's consolidated net profit surged to Rs 143.80 crore in the quarter ended December 2025 as against Rs 25.10 crore during the previous quarter ended December 2024. Sales rose 9.28% to Rs 4,123 crore in Q3 FY26 as compared with Q3 FY25.

Biocon announced the commercial launch of Bosaya' (denosumab-kyqq) and Aukelso' (denosumab kyqq) in the United States. Bosaya' (biosimilar to Prolia') and Aukelso' (biosimilar to Xgeva') are now available by prescription nationwide through specialty pharmacies and healthcare providers. Both products have been previously approved and granted interchangeable designation by the U.S. Food and Drug Administration in September 2025, allowing substitution at the pharmacy level in accordance with state laws. Shreehas Tambe, CEO & Managing Director, Biocon, said, 'The U.S. introduction of Bosaya' and Aukelso' marks a strategic expansion of our biosimilars portfolio, building on our established leadership in oncology and immunology. These therapies broaden access to high-quality, affordable treatment options for patients living with serious bone conditions. This milestone underscores Biocon's strength as a portfolio development engine and our focus on building the world's most scalable access platform'advancing life-changing medicines for patients and health systems across the United States and around the world.'

The company's board accepted the resignation of Siddharth Mittal as CEO and managing director, effective close of business hours on 31 March 2026. Mittal will transition into another leadership role within the Biocon Group and will cease to be key managerial personnel of the company. Based on the recommendation of the nomination and remuneration committee, the board approved Tambe's appointment as an additional director and CEO & MD for a period of five years, subject to shareholder approval. He will continue to serve as CEO and managing director of Biocon Biologics. Tambe brings nearly three decades of experience within the Biocon Group, having joined as a management trainee and rising through various leadership roles. Under his leadership, Biocon Biologics has emerged as one of the world's top five biosimilar companies by revenue, achieving a valuation of $5.5 billion in 2025. He played a key role in the acquisition and integration of Viatris' biosimilars business, helping build a fully integrated global biologics enterprise. He has also led the global expansion of the insulin business, including the establishment of a large integrated insulin manufacturing facility in Malaysia. An innovator by background, Tambe is credited with 61 patents and holds a master's degree in bioprocess technology from the Institute of Chemical Technology, Mumbai. In a parallel development, the board accepted the resignation of Mukesh Kamath as interim chief financial officer, effective 31 March 2026, as he takes on another role within the group. He will also step down as key managerial and senior management personnel. The company has appointed Kedar Narayan Upadhye as chief financial officer with effect from 1st April 2026. Upadhye, who currently serves as CFO of Biocon Biologics, will continue in that role alongside his new responsibilities. He brings over 23 years of experience across corporate finance, strategy, and investor relations, having previously held leadership positions at companies such as Cipla, Dr Reddy's Laboratories, PepsiCo, Thermax, and ReNew Energy Global. At Biocon Biologics, he played a key role in a landmark $800 million bond issuance listed on the Singapore Exchange, strengthening the company's financial flexibility and investor base. Further strengthening its leadership team, Biocon has designated Akhilesh Nand, Company Secretary of Biocon Biologics, as Head of Governance, Risk and Compliance, effective 1 April 2026. He has also been appointed as key managerial personnel and senior management personnel of the company from the same date. Akhilesh Nand is a seasoned legal and governance professional with over 25 years of multi-industry experience. He leads global governance functions at Biocon, covering corporate secretarial, risk management, compliance, internal audit, and investigations. He has played a key role in major M&A deals, including the merger of Ranbaxy Laboratories with Sun Pharmaceuticals and Biocon's acquisition of Viatris' biosimilars business. Over the past decade at Biocon, he has built and strengthened its legal, risk, compliance, and audit framework, while supporting large transactions, private equity fundraises, and strategic collaborations. Nand continues to serve as Company Secretary of Biocon Biologics and is known for aligning legal strategy with business objectives and driving strong corporate governance practices As part of broader organisational changes, the board designated Naveen Narayanan, Head of Global HR at Biocon Biologics (BBL), as the chief human resources officer of the company, effective 1 April 2026, and Mandar Shrikant Ghatnekar, Global Head of IT & Digital Transformation at BBL, as the chief technology officer, effective 1 April 2026. Both have been appointed as senior management personnel of the company from the same date. The Board also approved the cessation of certain senior management personnel, effective close of business hours on 31 March 2026. Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases. The company's consolidated net profit surged to Rs 143.80 crore in the quarter ended December 2025 as against Rs 25.10 crore during the previous quarter ended December 2024. Sales rose 9.28% to Rs 4,123 crore in Q3 FY26 as compared with Q3 FY25. Shares of Biocon slipped 1.88% to Rs 372.55 on the BSE. Powered by Capital Market - Live

The board of Biocon at its meeting held on 27 March 2026 has accepted the resignation of Mukesh Kamath, tendered vide his letter dated 20 March 2026, from the position of Interim Chief Financial Officer of the Company with effect from close of business hours of 31 March 2026 to take up another role within the Biocon Group. Further, the board has approved the appointment of Kedar Narayan Upadhye, Chief Financial Officer of Biocon Biologics, as the Chief Financial Officer (Key Managerial Personnel and Senior Management Personnel) of the Company, with effect from 01 April 2026. Powered by Capital Market - Live

The board of Biocon at its meeting held on 27 March 2026 has approved the appointment of Shreehas Pradeep Tambe (DIN: 09796480), Chief Executive Officer and Managing Director of Biocon Biologics (BBL), as an Additional Director of the Company w.e.f. 01 April 2026 and Chief Executive Officer and Managing Director (Key Managerial Personnel of the Company) for a period of 5 (five) years effective from 01 April 2026, subject to the approval of the shareholders of the Company. Powered by Capital Market - Live

The board of Biocon at its meeting held on 27 March 2026 has accepted the resignation of Siddharth Mittal (DIN: 03230757), tendered vide his letter dated 20 March 2026, from the position of Chief Executive Officer and Managing Director of the Company w.e.f. close of business hours of 31 March 2026 to transit into another leadership role within the Biocon Group. Powered by Capital Market - Live

Liraglutide is indicated for the treatment of insufficiently controlled type 2 diabetes mellitus in adults, adolescents, and children aged 10 years and above and is used as an adjunct to diet and exercise. The approval follows the US FDA's earlier clearance for Liraglutide injection (gSaxenda) that the company received on February 24, 2026. Biocon said the latest approval adds to its portfolio of vertically integrated, complex drug products. Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases. The company's consolidated net profit surged to Rs 143.80 crore in the quarter ended December 2025 as against Rs 25.10 crore during the previous quarter ended December 2024. Sales rose 9.28% to Rs 4,123 crore in Q3 FY26 as compared with Q3 FY25. Shares of Biocon rose 0.29% to Rs 393.85 on the BSE.Powered by Capital Market - Live

Biocon Ltd is up for a fifth straight session today. The stock is quoting at Rs 394.6, up 0.99% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.31% on the day, quoting at 25504.3. The Sensex is at 82333.07, up 0.13%. Biocon Ltd has gained around 8.04% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has gained around 5.55% in last one month and is currently quoting at 22632.05, up 1.62% on the day. The volume in the stock stood at 19.62 lakh shares today, compared to the daily average of 31.82 lakh shares in last one month. The benchmark March futures contract for the stock is quoting at Rs 397.7, up 1.21% on the day. Biocon Ltd is up 26.54% in last one year as compared to a 13.13% jump in NIFTY and a 13.84% jump in the Nifty Pharma index.The PE of the stock is 325.29 based on TTM earnings ending December 25.Powered by Capital Market - Live

Biocon has received approval from the U.S. FDA, for its complex formulation Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pens (gSaxenda'). Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management, indicated as an adjunct to a reduced-calorie diet and increased physical activity. GLP-1 receptor agonists have emerged as one of the fastest growing therapeutic classes globally, driven by the rising prevalence of obesity and metabolic disorders, strong clinical outcomes, and increasing physician adoption. Powered by Capital Market - Live

Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management, indicated as an adjunct to a reduced-calorie diet and increased physical activity. GLP-1 receptor agonists have emerged as one of the fastest growing therapeutic classes globally, driven by the rising prevalence of obesity and metabolic disorders, strong clinical outcomes, and increasing physician adoption. According to IQVIA MAT December 2025 the total addressable market opportunity for GLP-1 in weight loss in the U.S. was US $127 million. Siddharth Mittal, chief executive officer and managing director, Biocon, said: 'This timely approval of gSaxenda in the United States marks a defining milestone for Biocon, validating our scientific depth, our vertically integrated development and manufacturing platform, and our ability to bring complex drug products to markets around the world. GLP-1 therapies represent a significant growth driver for the company, with the U.S. being an important market in this strategy.' Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases. The company's consolidated net profit surged to Rs 143.80 crore in the quarter ended December 2025 as against Rs 25.10 crore during the previous quarter ended December 2024. Sales rose 9.28% to Rs 4,123 crore in Q3 FY26 as compared with Q3 FY25. The scrip rose 0.35% to currently trade at Rs 391.70 on the BSE. Powered by Capital Market - Live